Table 2.
Serum urate levels and rate of target serum urate levels in the whole population and by treatment subgroup analysis
| All patients (N = 506) | On ULTs (N = 482) | Not on ULTs (N = 24) | Allo (N = 363) | Feb (N = 108) | Bnz (N = 11) | |
|---|---|---|---|---|---|---|
| Baseline sUA (mg/dl) | 8.91 ± 1.68 | 8.94 ± 1.67 | 8.54* ± 1.70 | 8.71 ± 1.49 | 9.66 ± 1.90** | 9.40 ± 1.95 |
| Last sUA (mg/dl) | 5.79 ± 1.79 | 5.73 ± 1.76 | 6.86* ± 1.79 | 5.81 ± 1.54 | 5.52 ± 2.37 | 5.59 ± 1.92 |
| UA < 6 mg/dl at last visit (%) | 311/485 (64.33) | 302/457 (66.08) | 9/28* (32.14) | 226/348 (64.9) | 71/105 (67.6) | 8/11 (72.7) |
sUA serum uric acid, ULTs urate-lowering medications, Allo allopurinol, Feb febuxostat, Bnz benzbromarone
*p < 0.01 patients not on urate-lowering medications vs. patients on urate-lowering medications
** p < 0.01 patients on febuxostat vs. patients on allopurinol